Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles

Slides:

Advertisements

Similar presentations

Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles Ryan G. Steward,

Advertisements

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome Madelon van Wely, Ph.D.,

Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous.

Oral contraceptive pill pretreatment in ovarian stimulation with GnRH antagonists for IVF: a systematic review and meta-analysis George Griesinger, M.D.,

Oral contraceptive pretreatment significantly reduces ongoing pregnancy likelihood in gonadotropin-releasing hormone antagonist cycles: an updated meta-analysis

The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition Lorraine Dennerstein,

Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective,

Does the time interval between antimüllerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization–intracytoplasmic.

A prospective, randomized, double-blinded study of assisted hatching in women younger than 38 years undergoing in vitro fertilization Andrea R. Hagemann,

Value of the serum estradiol level for preventing ovarian hyperstimulation syndrome: a retrospective case control study Arianna D'Angelo, M.D., Rachel.

Effects and clinical significance of GnRH antagonist administration for IUI timing in FSH superovulated cycles: a meta-analysis Ioannis P. Kosmas, M.D.,

Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.

Possible metformin effect on adrenal androgens during pretreatment and IVF cycle in women with polycystic ovary syndrome Sigrun B. Kjøtrød, M.D., Arne.

The luteal phase of recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization cycles during supplementation.

A pituitary adenoma secreting follicle-stimulating hormone with ovarian hyperstimulation: treatment using a gonadotropin-releasing hormone antagonist

Cem Atabekoglu, M. D. , Murat Sonmezer, M. D. , Sinan Özkavukcu, M. D

Effect of the initiation of progesterone supplementation in in vitro fertilization–embryo transfer outcomes: a prospective randomized controlled trial

Day 4 Estradiol Levels Predict Pregnancy Success in Women Undergoing Controlled Ovarian Hyperstimulation for IVF John Y Phelps, M.D., Adam S Levine,

Cutoff value of human chorionic gonadotropin in relation to the number of methotrexate cycles in the successful treatment of ectopic pregnancy Ewa Nowak-Markwitz,

L. G. Maldonado, W. C. Busato, L. M. Rossi, T. C. Bonetti, A

The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count Simone L. Broer, B.Sc., Ben Willem J.

Grant D.E. McWilliams, D.O., John L. Frattarelli, M.D.

How old is too old? Challenges faced by clinicians concerning age cutoffs for patients undergoing in vitro fertilization Robert L. Klitzman, M.D. Fertility.

A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data

Improved monofollicular ovulation in anovulatory or oligo-ovulatory women after a low- dose step-up protocol with weekly increments of 25 international.

Subtle progesterone rise on the day of human chorionic gonadotropin administration is associated with lower live birth rates in women undergoing assisted.

Association of a single dose of gonadotropin-releasing hormone antagonist with nitric oxide and embryo quality in in vitro fertilization cycles Tsung-Hsien.

Effects of acupuncture on pregnancy rates in women undergoing in vitro fertilization: a systematic review and meta-analysis Cui Hong Zheng, M.D., Ph.D.,

Robert F. Casper, M.D. Fertility and Sterility

Looking back: egg donors' retrospective evaluations of their motivations, expectations, and experiences during their first donation cycle Nancy J. Kenney,

A comparison of three downregulation approaches for poor responders undergoing in vitro fertilization Laura Detti, M.D., Daniel B. Williams, M.D., Jared.

Ultrashort flare gonadotropin-releasing hormone (GnRH) agonist/GnRH antagonist protocol: a valuable tool in the armamentarium of ovulation induction for.

Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose.

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

Patients with severe ovarian hyperstimulation syndrome can be managed safely with aggressive outpatient transvaginal paracentesis Laura P. Smith, M.D.,

Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic.

How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis Dimitra Kyrou,

Venous thromboembolism in relation to in vitro fertilization: an approach to determining the incidence and increase in risk in successful cycles Karin.

Treatment of Ovarian Hyperstimulation Syndrome Utilizing a Dopamine Agonist and Gonadotropin Releasing Hormone antagonist N. Rollene, M. Amols, S. Hudson,

Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D.

Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro.

Gonadotropin-releasing hormone antagonist use is associated with increased pregnancy rates in ovulation induction–intrauterine insemination to in vitro.

Changes in cytokine levels of patients with ovarian endometriosis after treatment with gonadotropin-releasing hormone analogue, ultrasound-guided drainage,

Endocrine gland–derived vascular endothelial growth factor concentrations in follicular fluid and serum may predict ovarian hyperstimulation syndrome.

Abnormal endometrial development occurs during the luteal phase of nonsupplemented donor cycles treated with recombinant follicle-stimulating hormone.

José Bellver, M. D. , Yanira Ayllón, M. D. , Marcos Ferrando, M. D

In vitro fertilization and breast cancer: is there cause for concern?

Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series Nanette L. Rollene,

Effectiveness of highly purified human menopausal gonadotropin vs

Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis.

Moderately elevated levels of basal follicle-stimulating hormone in young patients predict low ovarian response, but should not be used to disqualify.

Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome Madelon van Wely, Ph.D.,

Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.

Administration of gonadotropin-releasing hormone antagonist from day 1 of stimulation in in vitro fertilization Efstratios M Kolibianakis, M.D., Kostas.

Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis Ernesto Bosch, M.D., Elena.

Effects of gonadotropin-releasing hormone agonist/recombinant follicle-stimulating hormone versus gonadotropin-releasing hormone antagonist/recombinant.

Cost-effectiveness comparison between pituitary down-regulation with a gonadotropin- releasing hormone agonist short regimen on alternate days and an antagonist.

First live birth after ovarian stimulation using a chimeric long-acting human recombinant follicle-stimulating hormone (FSH) agonist (recFSH-CTP) for.

Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists

Egg production predicts a doubling of in vitro fertilization pregnancy rates even within defined age and ovarian reserve categories Melissa C. Yih, M.D.,

Diane De Neubourg, M. D. , Kathelijne Mangelschots, B. Sc

Progesterone level and progesterone/estradiol ratio on the day of hCG administration: detrimental cutoff levels and new treatment strategy Eman A. Elgindy,

A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders Hakan Cakmak, M.D., Nam D. Tran,

A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for.

Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing.

In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation

Thyroid function after controlled ovarian hyperstimulation in women with and without the hyperstimulation syndrome Kris Poppe, M.D., Ph.D., David Unuane,

Logarithmic curves depicting initial level and rise of serum beta human chorionic gonadotropin and live delivery outcomes with in vitro fertilization:

The cumulative probability of liveborn multiples after in vitro fertilization: a cohort study of more than 10,000 women Beth A. Malizia, M.D., Laura.

Presentation transcript:

Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles Evangelos G. Papanikolaou, M.D., Ph.D., Cristina Pozzobon, M.D., Efstratios M. Kolibianakis, M.D., Ph.D., Michel Camus, M.D., Herman Tournaye, M.D., Ph.D., Human M. Fatemi, M.D., Andre Van Steirteghem, M.D., Ph.D., Paul Devroey, M.D., Ph.D. Fertility and Sterility Volume 85, Issue 1, Pages 112-120 (January 2006) DOI: 10.1016/j.fertnstert.2005.07.1292 Copyright © 2006 American Society for Reproductive Medicine Terms and Conditions

FIGURE 1 Analysis of ROC curve for E2 of >2,560 ng/L (area under the curve, 0.680) and for number of follicles ≥13 (area under the curve, 0.823). Difference between the two areas, 0.144 (95% CI = 0.055 to 0.232; P=.001). Solid line, E2 on hCG day; broken line, number of follicles. Papanikolauo. OHSS in GnRH-antagonist IVF cycles. Fertil Steril 2006. Fertility and Sterility 2006 85, 112-120DOI: (10.1016/j.fertnstert.2005.07.1292) Copyright © 2006 American Society for Reproductive Medicine Terms and Conditions

FIGURE 2 Estradiol values and number of follicles for each patient (n = 53) hospitalized for OHSS (in descending order according to the number of follicles). Papanikolauo. OHSS in GnRH-antagonist IVF cycles. Fertil Steril 2006. Fertility and Sterility 2006 85, 112-120DOI: (10.1016/j.fertnstert.2005.07.1292) Copyright © 2006 American Society for Reproductive Medicine Terms and Conditions